Axovant Sciences Ltd (NYSE:AXON) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

AXON has been the subject of a number of other reports. Jefferies Group LLC set a $40.00 price objective on shares of Axovant Sciences and gave the stock a “buy” rating in a report on Friday, August 25th. Evercore ISI started coverage on shares of Axovant Sciences in a research note on Friday, September 8th. They issued an “outperform” rating and a $30.00 target price on the stock. Chardan Capital reaffirmed a “sell” rating and issued a $3.00 target price on shares of Axovant Sciences in a research note on Saturday, September 23rd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $30.00 target price on shares of Axovant Sciences in a research note on Monday, September 25th. Finally, CIBC lifted their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. Axovant Sciences presently has an average rating of “Hold” and an average price target of $14.68.

Axovant Sciences (NYSE:AXON) opened at 7.05 on Thursday. The firm’s market capitalization is $758.05 million. Axovant Sciences has a 12 month low of $6.13 and a 12 month high of $27.98. The firm has a 50-day moving average of $15.77 and a 200 day moving average of $15.77.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). Equities research analysts forecast that Axovant Sciences will post ($2.02) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Axovant Sciences Ltd (AXON) Stock Rating Upgraded by BidaskClub” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/07/axovant-sciences-ltd-axon-stock-rating-upgraded-by-bidaskclub.html.

A number of institutional investors have recently modified their holdings of the business. Lord Abbett & CO. LLC purchased a new position in Axovant Sciences during the 2nd quarter valued at $696,000. California State Teachers Retirement System increased its position in Axovant Sciences by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock valued at $1,228,000 after purchasing an additional 4,800 shares during the period. The Manufacturers Life Insurance Company increased its position in Axovant Sciences by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock valued at $519,000 after purchasing an additional 3,184 shares during the period. State Street Corp increased its position in Axovant Sciences by 52.8% during the 2nd quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock valued at $12,682,000 after purchasing an additional 188,945 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in Axovant Sciences during the 2nd quarter valued at $47,854,000.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.